Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Genfit (GNFT)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
2.99 +0.05    +1.56%
11:35:12 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  France
ISIN:  FR0004163111 
  • Volume: 58,258
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 2.93 - 3.00
Genfit 2.99 +0.05 +1.56%

GNFT Financial Summary

 
A brief financial summary of Genfit as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

For the six months ended 30 June 2021, Genfit SArevenues decreased 42% to EUR3.4M. Net income totaledEUR9.1M vs. loss of EUR53M. Revenues reflect PublicFinancing of research expenditure decrease of 38% toEUR3.2M, Other Operating Income decrease of 66% to EUR174K,Revenue decrease of 91% to EUR11K. Net Income reflects R&DSubcontractors decrease of 38% to EUR15M (expense).

AnnualQuarterly
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

GNFT Income Statement

Gross margin TTM 72.49%
Operating margin TTM -520.91%
Net Profit margin TTM -736.08%
Return on Investment TTM -24.68%
 Total Revenue  Net Income
Period Ending: Jun 30, 2021 Dec 31, 2020 Jun 30, 2020 Dec 31, 2019
Total Revenue 3.43 1.89 5.87 35.6
Gross Profit 2.71 1.14 4.54 34.59
Operating Income 6.03 -33.73 -49.16 -11.9
Net Income 9.06 -48.21 -53.01 -14.01

GNFT Balance Sheet

Quick Ratio MRQ 3.92
Current Ratio MRQ 3.92
LT Debt to Equity MRQ 199.07%
Total Debt to Equity MRQ 207.89%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2021 Dec 31, 2020 Jun 30, 2020 Dec 31, 2019
Total Assets 133.71 198.61 256.2 309.85
Total Liabilities 101.15 214.78 224.82 225.79
Total Equity 32.57 -16.16 31.38 84.06

GNFT Cash Flow Statement

Cash Flow/Share TTM -0.87
Revenue/Share TTM 0.13
Operating Cash Flow  -89.83%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2021 Dec 31, 2020 Jun 30, 2020 Dec 31, 2019
Period Length: 6 Months 0 Months 6 Months 12 Months
Cash From Operating Activities -27.81 -96.37 -45.36 -47.68
Cash From Investing Activities 0.21 -0.97 -0.83 0.33
Cash From Financing Activities -38.97 -8.26 -4.83 116.85
Net Change in Cash -66.65 -105.72 -51.03 69.5
* In Millions of EUR (except for per share items)
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

GNFT Comments

Write your thoughts about Genfit
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Aynaz Rostami
Aynaz Rostami Feb 11, 2021 9:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what's the reason of fall of Genfit?
Reply
0 0
Report
ziqing liew
ziqing liew Feb 11, 2021 9:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i also want to know
Reply
1 0
Report
Aynaz Rostami
Aynaz Rostami Feb 11, 2021 9:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
dont worry it Will raise soon
Reply
0 0
Report
Thao Bui
Thao Bui Jun 26, 2020 4:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
it cheap to buy
Reply
0 0
Report
CAC Invest
CAC Invest Jun 09, 2020 5:39AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Trials for NASH will continue after dataset correction
Reply
0 1
Report
Thms Koprnk
Koprnk Jun 04, 2020 6:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
they failed the drug test and NASH drug was the only viable drug that they were developing , so practically they lost almost all value with that failure...
Reply
1 1
Report
CAC Invest
CAC Invest Jun 04, 2020 6:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
not all value but a drug development. they have so many programs to continue
Reply
1 0
Report
Danny Danny
Danny Danny May 21, 2020 1:03PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
damn what was wrong w this beast? from 2x all the way down to 5 w low volume?
Reply
1 0
Report
Rajaie Issaid
Rajaie Issaid May 20, 2020 4:15PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Whats the status , will it still go down ?
Reply
0 0
Report
Malek Brahmi
Malek Brahmi May 20, 2020 4:15PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Yes
Reply
0 0
Report
stats con chris
stats con chris May 19, 2020 2:27PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
this baby Is the brother of contravirpharma (HEPA) .. same diseases.
Reply
0 0
Report
MfB Iod
MfB Iod May 19, 2020 2:27PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what do you mean?
Reply
0 0
Report
Nedal Aysheh
Nedal Aysheh May 12, 2020 5:53PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
WHAT IS THE BEST STOCK TO BUY TODAY ??/ ANT RECOMMENDATION
Reply
1 0
Report
MfB Iod
MfB Iod Mar 27, 2019 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
does anyone have an explaination for the sudden fall same day of the Nasdaq trading?
Reply
1 0
Report
Show previous replies (5)
Mathieu Gandrille
Mathieu Gandrille Mar 27, 2019 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
MfB Iod  possible. today it will open low, in a range between 5 to 8. (my guess only - dyor)
Reply
0 0
Report
Mathieu Gandrille
Mathieu Gandrille Mar 27, 2019 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
MfB Iod   i changed my recommendation to SELL, with objective at 8.0
Reply
0 0
Report
MfB Iod
MfB Iod Mar 27, 2019 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Mathieu Gandrille  ah you mean to buy because it would be oversold
Reply
0 0
Report
Mathieu Gandrille
Mathieu Gandrille Mar 27, 2019 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
MfB Iod   i mean if 5 i would buy, and sell at 8
Reply
0 0
Report
Olivier Bclr
Olivier Bclr Mar 27, 2019 12:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Mathieu Gandrille  are you a KOL?
Reply
0 0
Report
P SH
P SH Nov 30, 2018 10:22AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
DATA is opn in 1Q 2019?
Reply
0 0
Report
Mathieu Gandrille
Mathieu Gandrille Nov 05, 2018 10:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Huge potential (x3-4 by Q1 2019) After results n PBC mid December. just by comparing with competitors market cap with similar pipeline (intercept, Gilead)
Reply
2 0
Report
P SH
P SH Nov 05, 2018 10:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
DATA is opn in 1Q 2019?
Reply
0 0
Report
Mathieu Gandrille
Mathieu Gandrille Nov 05, 2018 10:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Huge potential (x3-4 by Q1 2019) After results n PBC mid December. just by comparing with competitors market cap with similar pipeline (intercept, Gilead)
Reply
1 0
Report
MfB Iod
MfB Iod Nov 05, 2018 10:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
yep this is a sleeping giant
Reply
0 0
Report
MfB Iod
MfB Iod Oct 27, 2018 4:21PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
cannot understand how everyone is sleeping on this, unbelievable
Reply
0 0
Report
Giuliano Rossi
Cattalese Oct 27, 2018 4:21PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what do you mean?
Reply
0 0
Report
MfB Iod
MfB Iod Oct 27, 2018 4:21PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Giuliano Rossi  well the potential for this is huge and yet the market cap is 600m. Two NASH drugs one nearing Phase3 and the other about diagnostic which is non invasive and so far the only biotech that has this.
Reply
0 0
Report
Giuliano Rossi
Cattalese Oct 27, 2018 4:21PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
MfB Iod  i know, but it seems they want to hold all the markets for them, so always delaying the deadlines, the news and the progress.. They don't want to associate with other pharma to have the final product earlier.. and one big thing is that many hedge fund shorted it thats why it goes down, now only private like you and me have it.. . . But yes it has a HUGE potential.
Reply
0 0
Report
MfB Iod
MfB Iod Oct 27, 2018 4:21PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Giuliano Rossi  what do you mean hold all the markets for them? I don't think they are delaying. Their diagnostic product is the only one around and will be used with all the other NASH drugs in combination. I'm interested more in their diagnostic rather than the actual Elafibranor. Long GENFIT
Reply
0 0
Report
Giuliano Rossi
Cattalese Oct 27, 2018 4:21PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
MfB Iod  instead or dealing with other pharma a have a final product done, they want to do all by themself. by doing this they are late and late in every step. Mr. Mouney admit it.. Second this we've seen on continuous shares holding decrease cause people can't hold it anymore while it was always and always going down. from 33 to 17, off course at some point they exited.. Hopefully they will not postpone the result of phase 3 test...
Reply
0 0
Report
Giuliano Rossi
Cattalese Sep 04, 2018 11:49AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Nice topic here about genfit ahah :)
Reply
0 0
Report
Jerry DIVRAY
Jerry DIVRAY Jun 13, 2014 3:02AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The main competitor to Intercept is GENFIT, a pure golden nugget with a pluripotent molecule (GFT505) curing NASH and cardio vascular problems ( not like others, follow my eyes ..). . at the END of the 2b Phase,. . with an excellent safety independant report ,. . with a fast track agreement form the FDA .. FOR NASH ( follow again my eyes ). . and for an valuation 1/10 of is first competitor (follow my ..) ... . you can add that the Genfit molecule will be likely the first on the market for the NASH because of his safety report already published.. . the only problem ... it is an european molecule not easy to trade as US ones. . but on NASDAQ only next year .. better to get some before, the share is close to 34 $ ( with a close amount of shares). . code on the grey market GNFTF. . trading code GNFT.PA
Reply
0 0
Report
francis loos
francis loos Oct 22, 2013 11:34AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
repart demain haussier
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email